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article under the CC BY-NC-ND license (Abstract Background/purpose: The aim of this study is to investigate the effects of system-
ically administered boric acid on osteoporosis-related bone alterations, alveolar bone loss, re-
ceptor activator of nuclear factor kappa-b ligand (RANKL) expressions, and mandibular bone
density in experimental periodontitis model in osteoporotic rats.
Materials and methods: Thirty-six male Wistar rats were separated into five study groups: non-
ligated control (C, nZ 6) group; periodontitis (P, nZ 6) group; osteoporosis (O, nZ 8) group;
osteoporosis þ periodontitis (OþP, nZ 8) group, and osteoporosis þ periodontitis with 50 mg/
kg/d boric acid (BA50, nZ 8) group for 15 days. Osteoporosis was created with intraperitoneal
injection of 80 mg/kg retinoic acid for 15 days. Silk ligatures (4/0) were placed around the
mandibular right first molar teeth to induce experimental periodontitis. After induction of
osteoporosis and periodontitis, rats were sacrificed at Day 15. Alveolar bone loss was evaluated
with a stereomicroscope by measuring the distance from the cement-enamel junction to the
alveolar crest. Density measurements were performed on radiographs. RANKL and tartrate-
resistant acid phosphatase (TRAP) staining were performed on histological slides.
Results: Alveolar bone loss was significantly higher in the OþP group than those of the other
groups (P < 0.05). Boric acid decreased bone loss (P < 0.05). TRAP þ osteoclast numbers were
highest in the P group and lowest in the control group. The differences in TRAP þ osteoclast
numbers among control, P, OþP, and BA50 groups were significant (P < 0.05). There were
no significant differences in RANKL expression and mandibular bone density (P > 0.05).
Conclusion: Within limitations of this study, we conclude that boric acid may decrease alveolar
bone loss in a rat model with periodontitis and osteoporosis.
Copyright ª 2016, Association for Dental Sciences of the Republic of China. Published by Else-
vier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).of Periodontology, Gaziosmanpasa University, Faculty of Dentistry, Tokat 60100, Turkey.
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Osteoporosis is defined as “a systemic skeletal disease
characterized by low bone mass and micro-architectural
deterioration with consequent increase in bone fragility
and susceptibility to fracture.”1 Osteoporosis is not a life-
threatening disorder but still affects many people by
causing pain, disability, and diminished quality of life.2
Aging, estrogen deficiency, and inflammatory diseases are
the most common factors contributing to the development
of osteoporosis. There are some treatment procedures for
osteoporosis and these are mainly: calcium and vitamin D
reinforcement, antiresorptive agents such as bisphospho-
nates, selective estrogen receptor modulators, parathyroid
hormone, and surgery.2
The relationship between osteoporosis and oral health is
still a complex problem and the evidences are contradic-
tory. Some studies have suggested an association between
low skeletal bone mineral density (BMD) and periodontal
bone loss and tooth loss,3,4 while others have not.5,6
Furthermore, the mechanisms underlying any potential
association between periodontal disease and osteoporosis
are not fully understood but experimental studies of oste-
oporosis and periodontitis suggested a strong relation-
ship.7,8 In both diseases, there is an increased production of
cytokines that stimulate osteoclastic activity.8 Kobayashi
et al7 showed that alveolar bone mass was reduced by
ovariectomy and that estrogen deficiency significantly
enhanced the loss of alveolar bone in experimental peri-
odontitis in mice.
One of the most preferred treatment protocols for
osteoporosis is antiresorptive agents such as bisphospho-
nates. These drugs are very effective in preventing bone
resorption in long bones and vertebra but have a serious
side effect on jaws. Osteonecrosis caused by bisphospho-
nates makes any surgical dental procedure impossible and
it is very hard to treat.9
Being directly linked to bone metabolism,10 boron might
help reverse the effects of osteoporosis. Boron is the fifth
element in the periodic table and has the characteristics of
both metals and nonmetals. Boron interacts with calcium,
vitamin D, and magnesium. Boron is not found alone in
nature and is abundant in nature as boric acid (BA) and
borate. Boron can be obtained in the diet through the
consumption of fruits, vegetables (potato and avocado),
legumes, nuts, eggs, milk, wine, and dried foods.11 Many of
the foods that contain boron are likely to have beneficial
effects on bone.12 The daily requirement of boron has yet
to be defined, but daily multivitamin and mineral supple-
ments contain between 3 mg and 9 mg.12
Boron also has been shown to increase bone strength
measures in rats and found to be effective on early bone
regeneration in rabbits after expansion of midpalatal su-
ture.13 Hakkı et al10 showed that boron can induce osteo-
genesis by regulating RunX2, bone sialoprotein (mRNA
expression level), and bone morphogenetic protein-4, -6,
and -7 (protein level) in osteoblastic cells in vitro. Also,
Demirer et al14 reported that systemically administered BA
diminishes alveolar bone loss, decreases inflammatory cell
infiltrate, and increases osteoblastic activity in experi-
mental periodontitis in rats. In a previous study, we alsodemonstrated that 30 mg/kg and 50 mg/kg boric acid
decreased osteoclastic activity in diabetic rats.15
In an attempt to find an alternative treatment for
osteoporosis and based on these favorable aspects of BA,
we hypothesized that boron might be a potent suppressor
of bone loss in osteoporosis. Therefore, the aim of this
study is to investigate the effect of BA on alveolar bone loss
and mandibular bone density in osteoporotic rats with
periodontitis.
Materials and methods
Thirty-six male Wistar rats, with an average weight of
270e320 g, were used in this study. They were housed in
specially designed wire cages and maintained on a 12 hour/
12 hour light/dark cycle with a constant room temperature
of 23C. The protocol was approved by the Committee on
the Ethics of Animal Experiments of the Cumhuriyet Uni-
versity, Sivas, Turkey. Adequate measures were taken to
minimize pain or discomfort in animals. The animals were
randomly divided into five groups as follows: nonligated
control group (C, n Z 6); ligated periodontitis group (P,
n Z 6); osteoporosis only group (O, n Z 8); ligated peri-
odontitis and osteoporosis group (OþP, n Z 8); and ligated
osteoporosis with 50 mg/kg/d BA group (BA50, n Z 8).
Induction of osteoporosis
Twenty four rats were administered retinoic acid (80 mg/
kg). The other rats were administered sham injections.
Retinoic acid was mixed with olive oil and 0.5 mL of this
mixture was given to the rats via intraperitoneal injection
for 15 days.
Induction of experimental periodontitis
After osteoporosis was achieved in the groups, rats in the P,
OþP, and BA50 groups received ligature placement per-
formed under general anesthesia using ketamine (40 mg/
kg, Eczacibasi Ilac Sanayi, Istanbul, Turkey). A 4-0 silk su-
ture (Dogsan Ilac Sanayi, Istanbul, Turkey) was sub-
marginally placed around both the right and left first molars
of mandibular quadrants. The sutures were checked after
application, and lost or loose sutures were replaced. All
ligatures were placed by the same operator (H.B.Y.). The
animals were kept in individual cages and received water
and food ad libitum. BA was prepared as 50 mg/kg for 0.5-
mL distilled water and systemically administered by gastric
feeding at a rate of 0.5 mL daily for 15 days. The other rats
were administered saline solution. On Day 15, the animals
were sacrificed and the tissues were prepared for mor-
phometrical and histopathological analyses.
Measurement of alveolar bone loss
The mandibles were stained with aqueous methylene blue
(Merck & Co., Inc., Whitehouse Station, NJ, USA; 1%) to
identify the cemento-enamel junction. The alveolar bone
height was measured under a stereomicroscope (25
magnification; Stemi DV4, Carl Zeiss, Jena, Germany) by
recording the distance from the cemento-enamel junction
to the alveolar bone crest. Measurements were taken at
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the alveolar bone level. A mean value for each tooth was
calculated. The morphometric measurement of alveolar
bone loss was performed by a single examiner (H.T.) who
was unaware of the identity of samples.
BMD measurement
After the removal of the soft tissue around the left
mandible, digitalized X-ray investigations and BMD mea-
surements were performed. All radiographs were taken by
the same researcher (H.O.) with a digitalized intraoral
imaging system in the same conditions. Briefly, a radiation
tube was placed 10 cm far from a stabilized table. A certain
distance was settled between the mandible and the tube. A
5-mm metallic bar was placed onto a pink wax plate, which
had the same dimensions as the radiographic film. Standard
radiographs were taken with the same setting of the system
and then all images were transferred to an image analysis
program (ImageJ, National Institutes of Health, Bethesda,
MA, USA). BMD measurements were performed in a
standard-sized toothless area below the apices of the first
molar in all images.
Histopathological evaluations
Right mandibles were fixed in 10% neutral buffered
formalin. Tissues were then decalcified in a fixative-added
decalcification solution containing EDTA with a change
twice a week for 8 weeks until decalcification was
completed. The specimens were then dehydrated through
an ethanol series and embedded in paraffin. Each sample
was sliced into 5-mm continuous sections and prepared for
hematoxylin and eosin, histochemical staining for tartrate-
resistant acid phosphatase (TRAP), and immunohisto-
chemistry staining for inducible receptor activator of nu-
clear factor kappa-B ligand (RANKL). The periodontal
tissues around the mandibular first molar teeth were
examined. Inflammatory cell infiltration (ICI) was deter-
mined and ICI scoring was based on the inflammatory cell
accumulation around the first molars. ICI was determined
with a semiquantitative scoring as no visible ICI (0), slightly
visible ICI (1), moderately visible ICI (2), and the dense ICI
(3). Osteoblast cells, i.e., forming surfaces, by the visibility
of active bone formation surfaces that were bordered by
the osteoid and cuboidal osteoblasts in the examined area
were counted.
TRAP histochemistry
Deparaffinized sections were subjected to TRAP staining, to
identify osteoclasts. TRAP staining was performed accord-
ing to the manufacturer’s protocol using the TRAP staining
kit (Sigma-Aldrich, St Louis, MO, USA). Bright red staining of
the TRAPþ osteoclasts was closely monitored under the
microscope. Stained sections were washed in deionized
water and sections were counterstained with Gill’s hema-
toxylin and analyzed using light microscopy (Nikon Eclipse,
E 600; Nikon, Tokyo, Japan). Multinucleated giant cells with
ruffled border and resorption lacunae were considered tobe osteoclasts and TRAPþ osteoclast cells neighboring
periodontal ligament surrounding the tooth were counted.
RANKL immunohistochemistry
After deparaffinization and dehydration of the sections,
antigen retrieval was performed using 10mM sodium citrate
buffer (pH 6.0) for 2 hours at 70C. The sections were then
treated with 3% hydrogen peroxide to quench endogenous
peroxidase activity. After incubation with normal rabbit
serum for 30 minutes, samples were incubated with primary
antibodies overnight. The antibodies and conditions used
were as follows: goat polyclonal anti-inducible nitric oxide
synthase (Santa Cruz Biotechnology, Inc., Dallas, Texas,
U.S.A.; 1:100). After washing several times with phosphate-
buffered saline, the sections were incubated with bio-
tinylated immunoglobulin G for 30 minutes, washed several
times with phosphate-buffered saline, and reacted with
streptavidinehorseradish peroxidase conjugated reagent
for 30 minutes. Following 5-minute washes (3 times) with
phosphate-buffered saline, samples were incubated with
3,30-diaminobenzidine chromogen to visualize the immu-
noreactivity. Sections were counterstained with hematox-
ylin and analyzed using light microscopy (Nikon Eclipse, E
600; Nikon). Alveolar bone areas surrounding roots of the
first molars were examined and RANKL evaluation was made
by measuring the RANKLþ areas of the bone surrounding
teeth. The percentage of RANKLþ area to the examined
area was calculated. RANKL presence < 25% of the areas
surrounding teeth were scored as 1, 25e50% were scored as
2, 50e75% were scored as 3, and > 75% were scored as 4.
Statistical analysis
Data were presented as mean  standard deviation or
percentage as appropriate. Osteoclast and osteoblast
numbers, alveolar bone loss, RANKL, and mandibular bone
density were analyzed with analysis of variance followed by
Tukey test for pair-wise comparisons. A P value < 0.05 was
considered statistically significant.
Results
Experimental procedures were performed successfully and
there were no complications.
The presence of the silk ligature around the first molar
induced an inflammatory reaction in the periodontal tissue.
Measurement of alveolar bone loss in the mandibular molar
tooth revealed significantly higher bone loss values in the
OþP group compared with the other groups (P < 0.05;
Figure 1). Administration of BA decreased the negative ef-
fects of osteoporosis on periodontal destruction. The
lowest alveolar bone loss was 0.57 mm in the C group. Also,
there was no significant difference in alveolar bone loss
between the C and O groups (P > 0.05).
Histological sections from the C group showed normal
architecture in both the periodontal ligament and the
alveolar bone tissues. Sections from the O groups revealed
thinning of the bony trabeculae with multiple resorption
foci along the bone surface. The TRAP-positive osteoclast
cell numbers of the study groups are shown in Figure 2. The
Figure 1 Alveolar bone loss in the study groups. * P < 0.05
versus P, OþP, and BA50 groups. ** P < 0.05 versus OþP group.
*** P < 0.05 versus OþP and BA50 groups. **** P < 0.05 versus
BA50 group. BA50Z boric acid 50 mg/kg/d group; CZ control
group; O Z osteoporosis group; OþP Z osteoporosis and
periodontitis group.
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in the C group. The differences between the C and OþP
groups were significant (P < 0.05). The differences among
the other groups were not statistically significant
(P > 0.05). RANKL staining scores were lowest in the C
group and highest in the OþP group but the difference was
not statistically significant (P > 0.05; Figure 3).
Osteoblast number was highest in the BA50 group and
lowest in the O group. Although osteoblast number in the
experimental groups was decreased after osteoporosis in-
duction, the difference in osteoblast numbers did not reach
significance between P and BA50 groups (P > 0.05). The
osteoblast number in the O group was significantly lower
than C, P, and BA50 groups (P < 0.05) but there were no
significant differences between the O and OþP groups
(P > 0.05; Table 1).
Mandibular density measurements were highest in the
control group and lowest in the OþP group but there was no
significant difference among the groups either (P > 0.05;
Figure 4). The results are shown in Table 1.Figure 2 Osteoclast numbers in the study groups. * P < 0.05
versus OþP group. BA50 Z boric acid 50 mg/kg/d group;
CZ control group; OZ osteoporosis group; OþPZ osteoporosis
and periodontitis group.Discussion
Osteoporosis is a systemic disorder characterized by
reduced BMD throughout the skeletal system, including the
jaws, and compromises bone strength that predisposes to
increased risk of fracture, particularly hip fractures.16 In a
systematic review, it has been suggested that systemic
bone loss could increase the risk of osteoporotic fractures
affecting the mandible and increase the risk of developing
periodontitis.17 The correlation between periodontitis and
systemic osteoporosis is generally determined based on
radiological criteria, clinical criteria, or both. The results of
the studies are controversial; some studies found no rela-
tionship between osteoporosis and periodontitis and some
found a positive correlation.17,18 There is no standardiza-
tion in the studies investigating the relationship between
periodontitis and osteoporosis.17,18
Pharmacologic options for osteoporosis prevention or
treatment are bisphosphonates (alendronate, ibandronate,
risedronate, and zolendronic acid), teraparatide (para-
thyroid hormone N-terminal amino acids 1e34), estrogens,
the estrogen receptor modulators raloxifene or bazedox-
ifene, calcitonin, and the RANKL inhibitor denosumab.19
These drugs are also used in patients with metastasizing
bone disease.20 In spite of being very effective in osteo-
porosis treatment and preventing osteoprotic fractures,
these drugs might have serious side effects such as
medication-related osteonecrosis of the jaw.19
Bisphosphonate-related osteonecrosis of the jaw has been
characterized as the main side effect of bisphosphonate
therapy and it is a hard-to-treat condition.9,21
Recently boron was shown to promote skeletal health by
targeting the pathways of osteoblast and osteoclast differ-
entiation and survival of these cells.22 Ying et al22 reported
that boron can increase osteogenic effects by stimulating
osteogenic differentiation-related marker gene synthesis
during the proliferation and differentiation phase in human
bone marrow stromal cells and could be a promising
approach for enhancing osteogenic capacity. Boron increased
bone strength and bone ash content without detrimental
effects in chickens.23 Supplemental boron as BA has also been
shown to increase bone strength measures in rats.24 In addi-
tion, boron has been found to be effective in early bone
regeneration in rabbits after expansion of the midpalatal
suture.13 Also, it has been shown that boron increased the
mRNA expression of collagen type I, osteopontin, bone sia-
loprotein, osteocalcin, and RunX2 and protein levels of bone
morphogenetic protein-4, -6, and -7 in vitro.10
Boron might play a role in the maintenance of bone
metabolism, especially in the case of certain vitamin and
mineral deficiencies such as vitamin D, magnesium, and
potassium. It is reported that when there is no nutritional
deficiency or metabolic stress, the need for boron seems to
be low.25 Skeleton, kidney, and brain are the tissues most
affected by boron deprivation. Daily boron intake with diet
is in the range from 0.5 mg/d to 3.1 mg/d.26 Recently, we
have reported that 50 mg/kg BA decreased inflammation
and alveolar bone loss and increased osteoblastic activity in
diabetic Wistar rats.15 Furthermore, in this study, BA
administration decreased alveolar bone resorption via in-
duction of osteoblastic activity in retinoic acid-induced
osteoporotic rats with periodontitis.
Figure 3 Representative receptor activator of nuclear factor kappa-B ligand staining in the groups. Arrows indicate receptor
activator of nuclear factor kappa-B ligand positive staining areas. (A) Control group (200); (B) osteoporosis and periodontitis group
(200); (C) boric acid 50 mg/kg/d group (200).
Table 1 Osteoblast numbers and mandibular density
measurements in the study groups. Data are given as
mean  standard deviation.
Groups Osteoblast No. Mandibular density
C 39.16  20.59 0.39  0.03
P 30.83  6.64 0.38  0.02
O 20.66  6.68*,** 0.38  0.02
OþP 29.16  10.75* 0.36  0.03
BA50 49.16  18.00 0.39  0.01
* P < 0.05 versus P group.
** P < 0.05 versus BA50 group.
BA50 Z boric acid 50 mg/kg/d group; C Z control group;
O Z osteoporosis group; OþP Z osteoporosis and periodontitis
group.
Figure 4 Representative radiographic images of mandibles. (A) osteoporosis and periodontitis group; (B) boric acid 50 mg/kg/
d group.
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minerals. Boron, BA, and boron oxide are primarily irritants
under exposure conditions. Biochemical symptoms of
toxicity include riboflavinuria and riboflavin deficiency,
along with the inhibition of the dehydrogenase enzymes.
Toxic ingestions of boron may cause nausea, vomiting, and
diarrhea.27 A percentage of BA (17.48%) is boron and the fatal
dosages of boron for humans and rats are 640 mg/kg and
2660mg/kg, respectively. In our study we used the dosage of
50 mg/kg BA and this amount of BA contains 8.92 mg/kg
boron. Considering the average weight of the rats in our
study, the dose of boron given to the ratswas 2.95mgand this
dose is in the limits of daily consumption.12,26
Bone remodeling is a physiological process resulting from
the osteoblastic and osteoclastic activity. One of themediators mainly associated with bone remodeling is re-
ceptor of RANK, a very important cytokine for differentia-
tion and activation of osteoclasts. It was reported that the
administration of serum RANKL to mice promoted osteo-
clast growth and activation, leading to osteoporosis.
Expression of RANKL is a good indicator of osteoclastic ac-
tivity and bone loss. Recently it was found that boron is a
physiological regulator of the normal inflammatory
response,28,29 inhibits the activities of specific enzymes
involved in extracellular matrix turnover and metabolism,
and reduces RANKL expression. However, we found that BA
had no effect on RANKL expression in our study. In addition,
systemically administered BA did not reduce TRAPþ oste-
oclast cell numbers but diminished tissue destruction. The
percentages of the RANKLþ areas in periodontal ligaments
and alveolar bone within the groups were similar.Retinoic acid-induced osteoporosis model involved min-
imal trauma, rapid assaying, and was sensitive and specific.
Also, it was shown that serum calcium level, total body
BMD, and isolated left femora BMD after ashing had all
significantly decreased in retinoic acid-induced osteopo-
rotic rats.30 As an alternative for retinoic acid-induced
osteoporosis model, it is reasonable to consider the ovari-
ectomized female rat models for a postmenopausal osteo-
porosis study. However, the ovariectomized model should
be curtailed due to its longer and more complicated
experimental process.16,30 Besides, there are some limita-
tions of animal studies of osteoporosis. Osteoporosis is a
chronic disease mostly resulting from postmenopausal
hormone alterations.1,31 The alteration of bone tissue
observed in osteoporosis is a slowly progressive long process
336 H. Toker et aland the etiopathogenesis of osteoporosis is different from
other chronic inflammatory bone diseases. Unlike the slow
nature of the disease seen in humans, retinoic acid-induced
osteoporosis occurs in 15 days with a rapid change in rat
bone, mimicking secondary osteoporosis in humans.
Ligature methods have been accepted as useful experi-
mental models of periodontitis with alveolar bone
resorption.32e35 This ligature results in bacterial plaque
accumulation and triggers an inflammatory response,
reproducing human periodontal disease.32,35 In the present
study, ligature placement on the first molar tooth caused a
significant amount of bone loss and also, the amount of
bone loss was the highest in osteoporotic rats. However,
there are several limitations of animal studies. Firstly,
although molars in rats are similar in anatomic configura-
tion and structure to humans, they are smaller making it
difficult to perform any sort of periodontal treatment.
Secondly, another limitation of the experimental model
used is that the induced periodontitis follows an acute
course, during which tissue trauma and adjacent microbial
accumulation accelerate the destructive process. Such
pathways of acute inflammation are likely to differ from
chronic periodontitis.32,34
In conclusion, our results revealed that osteoporosis may
lead to enhanced alveolar bone loss in experimental peri-
odontitis. Furthermore, this study represents, within the
inherent limitations between experimental animal and
human disease interventions, the evidence that systemic
administration of BA decreases alveolar bone loss in
experimental periodontitis in osteoporotic rat models.
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